However, POLR3G was also identified in clinical data as one out of five genes in a risk signature predicting the prognosis of patients with hepatocellular carcinoma [44], significantly upregulated in transitional cell carcinoma [18], and increased POLR3G expression was detected in prostate tumor biopsies [17]. Here, POLR3G is linked to hepatocellular carcinoma.